C:\Program Files\Stnexp\Queries\10086781.str





chain nodes :
16
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
ring/chain nodes :
17 18
chain bonds :
1-16 16-17
ring/chain bonds :
17-18
ring bonds :
1-2 1-7 2-3 2-8 3-4 3-11 4-5 5-6 6-7 6-12 7-15 8-9 9-10 10-11 12-13 13-14
14-15
exact/norm bonds :
1-2 1-7 1-16 2-3 2-8 3-4 3-11 4-5 5-6 6-7 6-12 7-15 8-9 9-10 10-11 12-13
13-14 14-15 17-18
exact bonds :
16-17

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS

10/086,781

```
=> d his

     (FILE 'HOME' ENTERED AT 09:58:40 ON 28 SEP 2004)

     FILE 'REGISTRY' ENTERED AT 09:58:45 ON 28 SEP 2004
L1                STRUCTURE UPLOADED
L2                QUE L1
L3              6 S L2
L4            195 S L2 SSS FUL

     FILE 'CAPLUS' ENTERED AT 10:03:57 ON 28 SEP 2004
L5             29 S L4
                  SELECT RN L6 1-

     FILE 'REGISTRY' ENTERED AT 10:04:12 ON 28 SEP 2004
                  DEL SELECT
L6              1 S PYRROLIDINE/CN
L7        1119437 S 16.136/RID
L8         224460 S L7 AND NRS=4
L9           8986 S L8 AND BROMO
L10            47 S C28 H27 BR N2 O4/MF
L11             9 S L8 AND L10
L12            38 S L10 NOT L11
L13            14 S L12 AND NRS=4
L14       1150032 S METHOXYPHENYL
L15         53015 S L7 AND L14
L16             3 S BROMOBENZYL AND L15
L17          4428 S 2-BROMO AND L7
L18           155 S 4-METHOXY AND L17
L19            45 S L18 AND NRS=4
L20             1 S L19 AND C27 H27 BR N2 O4/MF
L21             1 S L19 AND C27 H27 BR N2 O3 S/MF
L22             1 S L19 AND C27 H31 BR N2 O S/MF
L23             3 S L20 OR L21 OR L22

     FILE 'CAPLUS' ENTERED AT 10:16:21 ON 28 SEP 2004
L24             2 S L23
L25            30 S L5 OR L24

=> d l2
L2 HAS NO ANSWERS
L1                STR
```



Structure attributes must be viewed using STN Express query preparation.
L2 QUE ABB=ON PLU=ON L1

=> d scan l23
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

L23 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN **2-Pyrrolidinemethanamine, N-[2-[[(2-bromophenyl)methyl]thio]phenyl]-1-[2-(4-methoxyphenyl)ethyl]-, (S)- (9CI)**
MF **C27 H31 Br N2 O S**

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L23 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN **2-Pyrrolidinecarboxamide, N-[2-[[(2-bromophenyl)methyl]thio]phenyl]-1-[(4-methoxyphenyl)acetyl]-, (S)- (9CI)**
MF **C27 H27 Br N2 O3 S**

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L23 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN **2-Pyrrolidinecarboxamide, N-[2-[(2-bromophenyl)methoxy]phenyl]-1-[(4-methoxyphenyl)acetyl]-, (2R)- (9CI)**
MF **C27 H27 Br N2 O4**

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d ibib abs hitstr 1-30 l25

L25 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:971921 CAPLUS
DOCUMENT NUMBER: 140:19879
TITLE: Drug compositions containing calcium channel antagonists exhibiting intestinal tract selectivity
INVENTOR(S): Hashimoto, Masaki; Takahashi, Kazuyoshi
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101490	A1	20031211	WO 2003-JP6847	20030530

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2002-160187 A 20020531
OTHER SOURCE(S): MARPAT 140:19879

AB Disclosed are a drug composition comprising a calcium channel antagonist exhibiting intestinal tract selectivity that is used for treating Alzheimer disease, mental illness, adolescent insanity, manic depression, migraine, lactation disorder, dementia, autism, hypertension, glaucoma, pain, thromboembolism, arrhythmia, epilepsy or obesity; and a serotonin liberation inhibitor comprising a calcium channel antagonist exhibiting intestinal tract selectivity. A compound (R)-3-chloro-5,11-dihydro-5-[1-(4-dimethylaminophenethyl)pyrrolidine-2-ylmethyl]dibenzo[b,e][1,4]oxazepine dihydrochloride (I) was prepared, and its effect on serotonin liberation in isolated mouse ileum was tested. A tablet containing I 50 mg/tablet was also formulated.

IT **477778-65-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(medicinal compns. containing calcium channel antagonists exhibiting intestinal tract selectivity)

RN 477778-65-7 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

IT **477778-53-3P 477778-55-5P 477778-57-7P**
477778-61-3P 477778-63-5P 477778-69-1P
477778-71-5P 477778-73-7P 477778-75-9P
477778-77-1P 477778-79-3P 477778-91-9P
477778-97-5P 630095-00-0P 630095-01-1P
630095-02-2P 630095-03-3P 630095-18-0P
630095-19-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(medicinal compns. containing calcium channel antagonists exhibiting intestinal tract selectivity)

RN 477778-53-3 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 477778-55-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 477778-57-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 477778-61-3 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 477778-63-5 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 477778-69-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-71-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-73-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-75-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-77-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-79-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-91-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-97-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 630095-00-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 630095-01-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 630095-02-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(3-pyridinyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-03-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-(5-pyrimidinyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-18-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, 3-chloro-N-[2-(5-methoxypyrazinyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 630095-19-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[6-(dimethylamino)-3-pyridinyl]ethyl]-7-fluoro-N-methyl- (9CI) (CA INDEX NAME)



IT **477778-66-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. containing calcium channel antagonists exhibiting intestinal tract selectivity)
RN 477778-66-8 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-

yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **16882-89-6 221161-17-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of calcium channel antagonists exhibiting intestinal tract selectivity)

RN 16882-89-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 221161-17-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(2R)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **477778-54-4P 477778-56-6P 477778-58-8P**
477778-60-2P 477778-62-4P 477778-64-6P
477778-68-0P 477778-70-4P 477778-72-6P
477778-74-8P 477778-76-0P 477778-78-2P
477778-80-6P 477778-92-0P 477778-98-6P
477779-17-2P 477779-22-9P 630095-20-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of calcium channel antagonists exhibiting intestinal tract selectivity)

RN 477778-54-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-56-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-58-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-60-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[(2R)-1-[2-(1,3-benzodioxol-5-yl)ethyl]-2-pyrrolidinyl]methyl]-7-chloro-5,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-62-4 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-64-6 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-68-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-70-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-72-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-74-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-76-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-78-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-80-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-92-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-98-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 477779-17-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5-[[(2R)-1-[[4-(dimethylamino)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]-5,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477779-22-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[[4-(1-pyrrolidinyl)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-20-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 98 THERE ARE 98 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:971920 CAPLUS
DOCUMENT NUMBER: 140:19878
TITLE: Medicinal compositions containing defined calcium channel antagonists for treatment for digestive tract disease
INVENTOR(S): Yamada, Youji; Takahashi, Kazuyoshi; Hashimoto, Masaki
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101489	A1	20031211	WO 2003-JP6845	20030530

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2002-160188 A 20020531
OTHER SOURCE(S): MARPAT 140:19878

AB Disclosed is a medicinal composition containing defined calcium channel antagonist, e.g. 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivative, 5,11-dihydrodibenzo[b,e][1,4]thiazepine derivative, etc., having a selectivity to digestive tract. The composition is used for treatments for diseases accompanied by an organic change of the digestive tract. A compound (R)-3-chloro-5,11-dihydro-5-[1-(4-dimethylaminophenethyl)pyrrolidine-2-ylmethyl]dibenzo[b,e][1,4]oxazepine dihydrochloride (I) was prepared, and its calcium channel blocking effect on isolated colon and ileum membranes. A tablet containing I 50 mg/tablet was also formulated.

IT **477778-65-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(medicinal compns. containing defined calcium channel antagonists for treatment for digestive tract disease)

RN 477778-65-7 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

IT **477778-54-4P 630095-20-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(medicinal compns. containing defined calcium channel antagonists for treatment for digestive tract disease)

RN 477778-54-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-20-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **477778-53-3P 477778-55-5P 477778-57-7P**
477778-61-3P 477778-63-5P 477778-69-1P
477778-71-5P 477778-73-7P 477778-75-9P
477778-77-1P 477778-79-3P 477778-91-9P
477778-97-5P 630095-00-0P 630095-01-1P
630095-02-2P 630095-03-3P 630095-19-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(medicinal compns. containing defined calcium channel antagonists for treatment for digestive tract disease)

RN 477778-53-3 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-55-5 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-57-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-61-3 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 477778-63-5 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 477778-69-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-71-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-73-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-75-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-77-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-79-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-91-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 477778-97-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 630095-00-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 630095-01-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 630095-02-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(3-pyridinyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-03-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-(5-pyrimidinyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630095-19-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[6-(dimethylamino)-3-pyridinyl]ethyl]-7-fluoro-N-methyl- (9CI) (CA INDEX NAME)



IT **477778-66-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. containing defined calcium channel antagonists for treatment for digestive tract disease)
RN 477778-66-8 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **630095-18-0P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nmedicinal compns. containing defined calcium channel antagonists for

treatment for digestive tract disease)
RN 630095-18-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, 3-chloro-N-[2-(5-methoxypyrazinyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



IT **16882-89-6 221161-17-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of medicinal compns. containing defined calcium channel antagonists
for treatment for digestive tract disease)
RN 16882-89-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 221161-17-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(2R)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **477778-56-6P 477778-58-8P 477778-60-2P**
477778-62-4P 477778-64-6P 477778-68-0P
477778-70-4P 477778-72-6P 477778-74-8P
477778-76-0P 477778-78-2P 477778-80-6P
477778-92-0P 477778-98-6P 477779-17-2P
477779-22-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of medicinal compns. containing defined calcium channel antagonists
for treatment for digestive tract disease)

RN 477778-56-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-58-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-60-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[(2R)-1-[2-(1,3-benzodioxol-5-yl)ethyl]-2-pyrrolidinyl]methyl]-7-chloro-5,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-62-4 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-64-6 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-68-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-70-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-72-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-74-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-76-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-78-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-80-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-92-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-98-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 477779-17-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5-[[(2R)-1-[[4-(dimethylamino)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]-5,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477779-22-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[[4-(1-pyrrolidinyl)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:644379 CAPLUS
DOCUMENT NUMBER: 139:173816
TITLE: Pharmaceutical compositions containing (biphenylcarboxamido)isoindoline derivatives as ApoB secretion inhibitors and hypolipemics
INVENTOR(S): Yamada, Harutami; Ando, Akira; Kawanishi, Hiroyuki; Nagata, Koichi; Yasuhara, Mikiko
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 75 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003231633	A2	20030819	JP 2002-29596	20020206
PRIORITY APPLN. INFO.:			JP 2002-29596	20020206

OTHER SOURCE(S): MARPAT 139:173816
GI



I

AB The derivs., useful for treatment of hyperlipemia, ischemic heart diseases, apoplexy, obesity, adiposis, constipation, etc., contain the title compds. I [A, B = (un)substituted benzene ring; Q = CO, CH2; R = (un)substituted lower alkyl, lower alkenyl, carbamoyl, heterocyclyl, aryl] or their pharmacol. acceptable salts. 2-(2-Pyridyl)acetyl-5-[2-(4-trifluoromethylphenyl)benzoylamino]isoindoline hydrochloride (II; preparation given) inhibited ApoB secretion by HepG2 cells at IC50 2.1 nM. Oral administration of II to rats 1 h prior to loading of olive oil lowered plasma triglyceride concentration at ED50 0.59 mg/kg.

IT **400726-74-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (biphenylcarboxamido)isoindoline derivs. as ApoB secretion inhibitors and hypolipemics)

RN 400726-74-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-dibenz[b,e][1,4]oxazepin-5(11H)-ylethyl)-2,3-dihydro-1H-isoindol-5-yl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L25 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:927415 CAPLUS
DOCUMENT NUMBER: 138:14080
TITLE: Preparation of dihydrodiaryloxazepine derivatives for treatment of functional digestive tract diseases
INVENTOR(S): Sakata, Katsutoshi; Tsuji, Takashi; Tokumasu, Munetaka; Takahashi, Kazuyoshi; Hirasawa, Shigeo; Ezaki, Junko
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096891	A1	20021205	WO 2002-JP5193	20020529
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1403258	A1	20040331	EP 2002-730742	20020529
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004110742	A1	20040610	US 2003-724179	20031201
PRIORITY APPLN. INFO.:			JP 2001-161988	A 20010530
			WO 2002-JP5193	W 20020529

OTHER SOURCE(S): MARPAT 138:14080
GI



I

AB The title compds. I [ring G, J, K = benzene ring or N-containing aromatic ring; R1 - R8 = halo, H; R9 - R13 = H, halo, cyano, etc.; A = CH2, etc.; B = CO, etc.; or AB = CH:CH; D = CH2, etc.; or BD = CH2; XZ = CH2CH2, CH2CH2CH2, and Y = H; or YZ = CH2CH2CH2, CH2CH2CH2CH2, and X = H; further detail on X, Y, Z is given; a proviso is given] are prepared Compds. of this invention are calcium channel antagonists with selectivity for the intestinal tract (IC50 values of 5.6 nM to 82.5 nM) and are useful in the treatment of functional digestive tract diseases. Formulations are given.

IT **195991-49-2P 195991-50-5P 477778-53-3P**
477778-54-4P 477778-55-5P 477778-56-6P
477778-57-7P 477778-58-8P 477778-59-9P
477778-60-2P 477778-61-3P 477778-62-4P
477778-63-5P 477778-64-6P 477778-65-7P
477778-66-8P 477778-67-9P 477778-68-0P
477778-69-1P 477778-70-4P 477778-71-5P
477778-72-6P 477778-73-7P 477778-74-8P
477778-75-9P 477778-76-0P 477778-77-1P
477778-78-2P 477778-79-3P 477778-80-6P
477778-91-9P 477778-92-0P 477778-97-5P
477778-98-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydrodiaryloxazepine derivs. for treatment of functional digestive tract diseases)

RN 195991-49-2 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-50-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 477778-53-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 477778-54-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-55-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 477778-56-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-57-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 477778-58-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-59-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[(2R)-1-[2-(1,3-benzodioxol-5-yl)ethyl]-2-pyrrolidinyl]methyl]-7-chloro-5,11-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 477778-60-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[(2R)-1-[2-(1,3-benzodioxol-5-yl)ethyl]-2-pyrrolidinyl]methyl]-7-chloro-5,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-61-3 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 477778-62-4 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-63-5 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-64-6 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-65-7 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 477778-66-8 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-67-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-68-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-69-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-70-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-71-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-72-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-73-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-74-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-75-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 477778-76-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-77-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 477778-78-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-79-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 477778-80-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[(2R)-1-[2-[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-91-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477778-92-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-97-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 477778-98-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



IT **221161-17-7 281677-99-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of dihydrodiaryloxazepine derivs. for treatment of functional digestive tract diseases)
RN 221161-17-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(2R)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-99-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl- (9CI) (CA INDEX NAME)



IT **477779-17-2P 477779-22-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydrodiaryloxazepine derivs. for treatment of functional digestive tract diseases)
RN 477779-17-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5-[[(2R)-1-[[4-(dimethylamino)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]-5,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477779-22-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[(2R)-1-[[4-(1-pyrrolidinyl)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:465986 CAPLUS
DOCUMENT NUMBER: 137:33327
TITLE: Process for preparing crystals of oxazepine derivatives
INVENTOR(S): Matsuzawa, Toshihiro; Sekiyama, Takaaki; Yatagai, Masanobu
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048120	A1	20020620	WO 2000-JP8739	20001211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001017359	A5	20020624	AU 2001-17359	20001211
PRIORITY APPLN. INFO.:			WO 2000-JP8739 A	20001211
OTHER SOURCE(S):		CASREACT 137:33327		

AB This document discloses a process which comprises dissolving in a solvent a mixture of optically active 5,11-dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine (I) with optically active 5,11-dihydro-5-[1-[2-(4-methoxyphenyl)ethyl]piperidin-3-yl]dibenzo[b,e][1,4]oxazepine, adding nitric acid to the obtained solution to precipitate crystals, and separating these crystals from the resulting system. I is a known calcium antagonist for the treatment of irritable bowel syndrome.

IT **195991-49-2P 195991-50-5P 313048-22-5P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for preparing crystals of oxazepine derivs.)

RN 195991-49-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-50-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 313048-22-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 195991-49-2
CMF C27 H30 N2 O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7697-37-2
CMF H N O3



IT **437703-61-2P 437703-62-3P 437703-63-4P**
RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(process for preparing crystals of oxazepine derivs.)
RN 437703-61-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 437703-62-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 437703-61-2
CMF C27 H30 N2 O2



CM 2

CRN 7697-37-2
CMF H N O3



RN 437703-63-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:142672 CAPLUS
DOCUMENT NUMBER: 136:200094
TITLE: Preparation of biphenylcarboxamidoisoindoline derivatives as apolipoprotein B secretion inhibitors
INVENTOR(S): Yamada, Harutami; Ando, Akira; Kawanishi, Hiroyuki; Nagata, Koichi; Yasuhara, Mikiko
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014277	A1	20020221	WO 2001-JP6844	20010809
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001077728	A5	20020225	AU 2001-77728	20010809
JP 2003055345	A2	20030226	JP 2001-241482	20010809
PRIORITY APPLN. INFO.:			JP 2000-243004 A	20000810
			JP 2001-172918 A	20010607
			WO 2001-JP6844 W	20010809

OTHER SOURCE(S): MARPAT 136:200094
GI



I

AB The title compds. I [ring A is a substituted or unsubstituted benzene ring; ring B is a substituted or unsubstituted benzene ring; Q is CO or CH2; and R is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted carbamoyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like], useful as apolipoprotein B secretion inhibitors (no data), are prepared Processes for the preparation of I are claimed. For example, 2-(2-pyridyl)acetyl-5-[2-(4-trifluoromethylphenyl)benzoylamino]isoindoline was prepared

IT **400726-74-1P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); USES (Uses)
(preparation of biphenylcarboxamidoisoindoline derivs. as apolipoprotein B secretion inhibitors)

RN 400726-74-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-dibenz[b,e][1,4]oxazepin-5(11H)-ylethyl)-2,3-dihydro-1H-isoindol-5-yl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:185738 CAPLUS
DOCUMENT NUMBER: 134:222732
TITLE: Novel processes for preparing oxazepine derivatives via cyclization of 2-(2-bromobenzyloxy)aniline derivative
INVENTOR(S): Sekiyama, Takaaki; Matsuzawa, Toshihiro; Yamamoto, Takashi; Yatagai, Masanobu; Ezaki, Junko
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001017980	A1	20010315	WO 2000-JP5967		20000901
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 2000068689	A5	20010410	AU 2000-68689		20000901
EP 1219611	A1	20020703	EP 2000-956884		20000901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
US 2002133004	A1	20020919	US 2002-86781		20020304
PRIORITY APPLN. INFO.:			JP 1999-250298	A	19990903
			WO 2000-JP5967	W	20000901

OTHER SOURCE(S): CASREACT 134:222732; MARPAT 134:222732
GI



I



II

AB Industrially advantageous processes for preparing 5-substituted-5,11-dihydrodibenz[b,e][1,4]oxazepine derivs. (I; Z = CH2: Y1 = H; Y2 = H, lower alkyl; or Y1 and Y2 together represent (CH2)3 or (CH2)4; Y3 = CH2, CH2CH2; R1 - R5 = H, halo, lower alkyl, HO, lower alkoxy, NH2, lower alkylamino; or R1 and R2, R2 and R3, R3 and R4, or R4 and R5 together represents OCH2O) through intramol. arylation and reduction from [2-(2-bromobenzyloxy)phenyl]amide derivs. bearing via amide linkage substituents to be introduced at the 5-position are described. More particularly, a process comprises subjecting (R)-1-[(4-methoxyphenyl)acetyl]pyrrolidine-2-carboxylic [2-(2-bromobenzyloxy)phenyl]amide (II; Y1- Y3, R1-R5 = same as above) to intramol. arylation to form (R)-[[2-(5,11-dihydrodibenz[b,e][1,4]oxazepine-5-carbonyl)pyrrolidin]-1-yl]-2-(4-methoxyphenyl)ethanone I (Z = CO; Y1-Y3, R1-R5 = same as above) and then reducing the obtained compound The compds. I possesses calcium channel antagonism and are useful for the prevention or treatment of digestive tract motility disorders, in particular intestinal disorders such as irritable bowel syndrome. Thus, (R)-1-[(4-methoxyphenyl)acetyl]pyrrolidine-2-carboxylic acid [2-(2-bromobenzyloxy)phenyl]amide (preparation given) (1.69 kg), 23.0 g CuBr, and 443 g K2CO3 were added to 4.19 L pyridine and heated under reflux for 100 h to give, after workup and silica gel chromatog., 1.35 kg (R)-[2-[(5,11-dihydrodibenzo[b,e][1,4]oxazepin-5-yl)carbonyl]pyrrolidin-1-yl]-2-(4-methoxyphenyl)ethanone (95% yield). A solution of the latter compound (1.35 kg) in 2.69 L THF was added to a cooled (5°) suspension of 400 g NaBH4 in 19.77 L THF, treated dropwise with 1.97 kg BF3-THF complex at ≤10°, stirred at 5° for 1 h and 40° for 14 h, cooled at 5°, treated dropwise with 13.6 L 1.5 M aqueous NaOH, and stirred at 60° for 2 h. The reaction mixture was extracted with 8.1 L PhMe and the organic layer was concentrated in vacuo to .apprx.7.5 L, washed with water three times, warmed at 30°, treated dropwise with 941 L 4 M HCl/EtOAc, stirred at 5° overnight, and filtered to collect precipitated crystals which ere recrystd. from 2-propanol to give 1.00 kg (R)-(+)-5,11-dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine hydrochloride (73%).

IT **329329-17-1P 329329-18-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(novel processes for preparing oxazepine derivs. via cyclization of (bromobenzyloxy)aniline derivative)

RN 329329-17-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-[(2-bromophenyl)methoxy]phenyl]-1-[(4-methoxyphenyl)acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 329329-18-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[(4-methoxyphenyl)acetyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **195991-50-5P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel processes for preparing oxazepine derivs. via cyclization of (bromobenzyloxy)aniline derivative)
RN 195991-50-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:889402 CAPLUS
DOCUMENT NUMBER: 134:42148
TITLE: Preparation of crystals of oxazepines for treatment of irritable colon syndrome
INVENTOR(S): Matsusawa, Toshihiro; Sekiyama, Takaaki; Yatagai, Masanobu
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000351778	A2	20001219	JP 1999-162760	19990609
PRIORITY APPLN. INFO.:			JP 1999-162760	19990609

OTHER SOURCE(S): CASREACT 134:42148

AB 5,11-Dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine nitrate (I), useful treatment of irritable colon syndrome, etc. (no data), is prepared by reaction of 5,11-dihydrodibenzo[b,e][1,4]oxazepine with optically active 3-chloro-1-(4-methoxyphenethyl)piperidine, reaction of the resulting mixts. containing optically active 5,11-dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine (II) and 5,11-dihydro-5-[1-[2-(4-methoxyphenyl)ethyl]piperidin-3-yl]dibenzo[b,e][1,4]oxazepine (III) in HNO3 in solvents, and isolation of I by crystallization 5,11-Dihydrodibenzo[b,e][1,4]oxazepine was reacted with (S)-(+)-3-chloro-1-(4-methoxyphenethyl)piperidine in the presence of NaH in DMSO at 50° for 5 h to give 7.3:1 mixture of (R)-(+)-II and (S)-III, which was reacted with HNO3 in EtOH at room temperature overnight to give 43.7% (R)-I.

IT **195991-49-2P**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of crystals of oxazepines by condensation of benzooxazepine with chloropiperidine and reaction with nitric acid)

RN 195991-49-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **313048-22-5P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystals of oxazepines by condensation of benzooxazepine with chloropiperidine and reaction with nitric acid)

RN 313048-22-5 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 195991-49-2
CMF C27 H30 N2 O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7697-37-2
CMF H N O3



IT **195991-50-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of crystals of oxazepines by condensation of benzooxazepine with chloropiperidine and reaction with nitric acid)
RN 195991-50-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L25 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:475653 CAPLUS
DOCUMENT NUMBER: 133:89556
TITLE: Preparation of oxazepine derivatives and drugs containing the same
INVENTOR(S): Sakata, Katsutoshi; Tsuji, Takashi; Sasaki, Noriko; Takahashi, Kazuyoshi
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040570	A1	20000713	WO 2000-JP71	20000111
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1142884	A1	20011010	EP 2000-900167	20000111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002099047	A1	20020725	US 2001-899928	20010709
US 6528504	B2	20030304		

PRIORITY APPLN. INFO.:		
JP 1999-3268	A	19990108
JP 1999-3269	A	19990108
JP 1999-3270	A	19990108
WO 2000-JP71	W	20000111

OTHER SOURCE(S): MARPAT 133:89556
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; A = Q, Q1, Q2; R = H, Cl, (CH3)2N, CH3O; R1 = CH3O, N(CH3)2, H; R-R1 = OCH2O; n = 2, 3;], salts, stereoisomers, and drug compns. containing I are prepared and are useful in the treatment or prevention of motor function disorder of digestive tract, particularly intestinal diseases including irritable bowel syndrome. Thus, the title compds. (R)-5,11-Dihydro-5-[1-(4-methoxyphenethyl)-piperidin-2-ylmethyl]dibenzo[b,e][1,4] oxazepine and (R)-5,11-dihydro-5-[1-(4-dimethylaminophenethyl)-piperidin-2-ylmethyl]dibenzo[b, e][1,4]oxazepin were prepared and tested.
IT **281677-32-5P 281677-34-7P 281677-35-8P**
281677-36-9P 281677-37-0P 281677-38-1P
281677-45-0P 281677-46-1P 281677-47-2P
281677-48-3P 281677-49-4P 281677-50-7P
281677-51-8P 281677-52-9P 281677-53-0P
281677-56-3P 281677-57-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazepine derivs. and drugs containing the same)

RN 281677-32-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 281677-34-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2S)-1-[2-(3-methoxyphenyl)ethyl]-2-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 281677-35-8 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[3-(4-methoxyphenyl)propyl]-2-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 281677-36-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[(2R)-1-[2-(1,3-benzodioxol-5-yl)ethyl]-2-piperidinyl]methyl]-5,11-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 281677-37-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[(2R)-1-[2-(4-chlorophenyl)ethyl]-2-piperidinyl]methyl]-5,11-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 281677-38-1 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-piperidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 281677-45-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(4-methoxyphenyl)ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 281677-46-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(3-methoxyphenyl)ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 281677-47-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[3-(4-methoxyphenyl)propyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 281677-48-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 281677-49-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(4-chlorophenyl)ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 281677-50-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[4-(dimethylamino)phenyl]ethyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



RN 281677-51-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[3-(dimethylamino)phenyl]ethyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281677-52-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-53-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2S)-1-[2-(3-methoxyphenyl)ethyl]-2-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-56-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(4-methoxyphenyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 281677-57-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(3-methoxyphenyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



IT **281677-61-0P 281677-64-3P 281677-67-6P**
281677-70-1P 281677-73-4P 281677-98-3P
281677-99-4P 281678-00-0P 281678-01-1P
281678-02-2P 281678-03-3P 281678-04-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazepine derivs. and drugs containing the same)

RN 281677-61-0 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(3-methoxyphenyl)ethyl]-2-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-64-3 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[3-(4-methoxyphenyl)propyl]-2-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-67-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[(2R)-1-[2-(1,3-benzodioxol-5-yl)ethyl]-2-piperidinyl]methyl]-5,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-70-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[(2R)-1-[2-(4-chlorophenyl)ethyl]-2-piperidinyl]methyl]-5,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-73-4 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-piperidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 281677-98-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-acetamide, N-methyl- (9CI) (CA INDEX NAME)



RN 281677-99-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl- (9CI) (CA INDEX NAME)



RN 281678-00-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[3-(4-methoxyphenyl)propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 281678-01-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 281678-02-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(4-chlorophenyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 281678-03-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[4-(dimethylamino)phenyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 281678-04-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[3-(dimethylamino)phenyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



IT **281677-33-6P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazepine derivs. and drugs containing the same)
RN 281677-33-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2S)-1-[2-(4-methoxyphenyl)ethyl]-2-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:404950 CAPLUS
DOCUMENT NUMBER: 131:58843
TITLE: preparation of 3-piperidyl-4-oxoquinazoline derivatives as medicinal compositions
INVENTOR(S): Sato, Motohide; Katsushima, Takeo; Kinoshita, Hajime
PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9931085	A1	19990624	WO 1998-JP5628		19981211
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
JP 11228569	A2	19990824	JP 1998-288979		19981012
JP 2959765	B2	19991006			
ZA 9811315	A	19990630	ZA 1998-11315		19981210
AU 9915068	A1	19990705	AU 1999-15068		19981211
AU 717963	B2	20000406			
EP 970954	A1	20000112	EP 1998-959187		19981211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO					
BR 9807339	A	20000321	BR 1998-7339		19981211
TR 9901933	T1	20000321	TR 1999-9901933		19981211
NZ 337118	A	20000327	NZ 1998-337118		19981211
NO 9903868	A	19991012	NO 1999-3868		19990811
US 6235730	B1	20010522	US 1999-367242		19991026
PRIORITY APPLN. INFO.:			JP 1997-362819	A	19971212
			JP 1998-288979	A	19981012
			WO 1998-JP5628	W	19981211

OTHER SOURCE(S): MARPAT 131:58843
GI



I

AB 3-Piperidyl-4-oxoquinazoline derivs. or pharmaceutically acceptable salts [I; R = amino substituted by optionally substituted aryl, heteroaryl, or cyclic amino such as dibenzazepine; n = integer from 1 to 4; R3, R4 = H, lower alkyl, etc.], having an excellent MTP-inhibitory activity, thus

useful in inhibiting the formation of LDL causative of arteriosclerotic diseases and enabling the regulation of TG, cholesterol and lipoproteins such as LDL in the blood and cellular lipids via the regulation of the MTP activity, were prepared I are expected also as a novel type of remedies or preventives for hyperlipemia or arteriosclerotic diseases and, moreover, as remedies or preventives for pancreatitis, obesity, hypercholesterolemia, hypertriglyceridemia, etc. Refluxing a mixture of BrCH2CH2NPh2 and 3-(piperidin-4-yl)-3H-quinazolin-4-one containing K2CO3 in MeCN gave 55% I (R = Ph2N, R3 = R4 = H, n = 2) (II). II.2HCl showed IC50 of 0.1 μM against apolipoprotein B secretion and 0.6 μM against triglyceride transport in vitro.

IT **227806-80-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-piperidyl-4-oxoquinazoline derivs. as medicinal compns.)

RN 227806-80-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[1-(2-dibenz[b,e][1,4]oxazepin-5(11H)-ylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



IT **227806-33-9P 227806-34-0P 227806-35-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3-piperidyl-4-oxoquinazoline derivs. as medicinal compns.)

RN 227806-33-9 CAPLUS

CN Carbamic acid, [1-(2-dibenz[b,e][1,4]oxazepin-5(11H)-ylethyl)-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 227806-34-0 CAPLUS
CN 4-Piperidinamine, 1-(2-dibenz[b,e][1,4]oxazepin-5(11H)-ylethyl)- (9CI) (CA INDEX NAME)



RN 227806-35-1 CAPLUS
CN Benzamide, 2-amino-N-[1-(2-dibenz[b,e][1,4]oxazepin-5(11H)-ylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:194140 CAPLUS
DOCUMENT NUMBER: 130:223305
TITLE: Preparation and formulation of 5,11-dihydrodibenz[b,e][1,4]oxazepine derivatives as calcium antagonists
INVENTOR(S): Sakata, Katsutoshi; Tsuji, Takashi; Sasaki, Noriko; Takahashi, Kazuyoshi
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9912925	A1	19990318	WO 1998-JP4071		19980910
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2304262	AA	19990318	CA 1998-2304262		19980910
AU 9890014	A1	19990329	AU 1998-90014		19980910
AU 740878	B2	20011115			
EP 1020466	A1	20000719	EP 1998-941803		19980910
EP 1020466	B1	20030219			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI					
AT 232861	E	20030315	AT 1998-941803		19980910
US 6562808	B1	20030513	US 2000-522946		20000310
PRIORITY APPLN. INFO.:			JP 1997-245669	A	19970910
			JP 1997-245670	A	19970910
			WO 1998-JP4071	W	19980910

OTHER SOURCE(S): MARPAT 130:223305
GI



I

AB The title compds. I [R1 - R5 = H, alkoxy, etc.; R6, R7 = H, hydroxy; Y1 = methylene, etc.] are prepared I are useful in the treatment or prevention of intestinal diseases such as gastrointestinal tract dyskinesia, in particular, irritable bowel syndrome. In an in vitro test for calcium antagonism using ileum, (R)-5,11-Dihydro-5-[1-[2-(4-dimethylaminophenyl)ethyl]-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine dihydrochloride (II) in vitro showed IC50 of 35 nM; in an in vitro test for calcium antagonism using artery, II showed IC50 of 255 nM. I also showed high water solubility

IT **221159-49-5P 221159-53-1P 221159-56-4P**
221159-60-0P 221159-63-3P 221159-66-6P
221159-69-9P 221159-72-4P 221159-75-7P
221159-77-9P 221159-80-4P 221159-84-8P
221159-91-7P 221159-97-3P 221160-01-6P
221160-05-0P 221160-09-4P 221160-13-0P
221160-22-1P 221160-29-8P 221160-36-7P
221160-44-7P 221160-51-6P 221160-58-3P
221160-64-1P 221160-70-9P 221160-75-4P
221160-82-3P 221160-86-7P 221160-90-3P
221160-94-7P 221160-99-2P 221161-03-1P
221161-07-5P 221161-10-0P 221161-13-3P
221161-14-4P 221161-15-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydrodibenzoxazepine derivs. as calcium antagonists)

RN 221159-49-5 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221159-53-1 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221159-56-4 CAPLUS
CN Benzenamine, 4-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221159-60-0 CAPLUS
CN Benzenamine, 4-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221159-63-3 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221159-66-6 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221159-69-9 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221159-72-4 CAPLUS
CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221159-75-7 CAPLUS
CN Benzenamine, 3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221159-77-9 CAPLUS
CN Benzenamine, 3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221159-80-4 CAPLUS
CN Benzenamine, 3-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221159-84-8 CAPLUS
CN Benzenamine, 3-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221159-91-7 CAPLUS
CN Benzenamine, 3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221159-97-3 CAPLUS
CN Benzenamine, 3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221160-01-6 CAPLUS
CN Benzenamine, 3-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221160-05-0 CAPLUS
CN Benzenamine, 2-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221160-09-4 CAPLUS
CN Benzenamine, 2-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221160-13-0 CAPLUS
CN Benzenamine, 2-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221160-22-1 CAPLUS
CN Benzenamine, 5-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-2-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221160-29-8 CAPLUS
CN Benzenamine, 5-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-2-methoxy-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221160-36-7 CAPLUS
CN Benzenamine, 5-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 221160-44-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[3-(4-methoxyphenyl)propyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221160-51-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[3-(4-methoxyphenyl)propyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 221160-58-3 CAPLUS
CN 1-Pyrrolidinepropanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-α-phenyl-, (αS,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221160-64-1 CAPLUS
CN 1-Pyrrolidinepropanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-α-phenyl-, monohydrochloride, (αS,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 221160-70-9 CAPLUS
CN 1-Pyrrolidinepropanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-α-phenyl-, (αR,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221160-75-4 CAPLUS
CN 1-Pyrrolidinepropanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-α-phenyl-, monohydrochloride, (αR,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 221160-82-3 CAPLUS
CN 1-Pyrrolidineethanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-α-[(4-methoxyphenyl)methyl]-, (αR,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221160-86-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-(3-phenyl-2-propenyl)-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 221160-90-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-(3-phenyl-2-propenyl)-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



● HCl

RN 221160-94-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenoxy)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221160-99-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenoxy)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 221161-03-1 CAPLUS
CN Benzenamine, 4-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-07-5 CAPLUS
CN Benzenamine, 4-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221161-10-0 CAPLUS
CN Benzenamine, 3-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-13-3 CAPLUS

CN Benzenamine, 3-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 221161-14-4 CAPLUS
CN Benzenamine, 3-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-15-5 CAPLUS
CN Benzenamine, 3-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

IT **221161-16-6P 221161-17-7P 221161-18-8P**
221161-19-9P 221161-20-2P 221161-21-3P
221161-24-6P 221161-25-7P 221161-26-8P
221161-29-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydrodibenzoxazepine derivs. as calcium antagonists)

RN 221161-16-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-17-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(2R)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-18-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(2S)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-19-9 CAPLUS
CN Carbamic acid, [4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-20-2 CAPLUS
CN Carbamic acid, [4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-21-3 CAPLUS
CN Carbamic acid, [3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-24-6 CAPLUS
CN Carbamic acid, [3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-25-7 CAPLUS
CN Carbamic acid, [3-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-26-8 CAPLUS
CN Carbamic acid, [2-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221161-29-1 CAPLUS
CN Carbamic acid, [5-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-2-methoxyphenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:623166 CAPLUS
DOCUMENT NUMBER: 127:293256
TITLE: Preparation and formulation of 5,11-dihydrodibenz[b,e][1,4]oxazepine derivatives for improving the motor function of the digestive tract
INVENTOR(S): Tanaka, Yuji; Misumi, Keiji; Kawakami, Yoshinari; Moriguchi, Masahiko; Takahashi, Kazuyoshi; Okamoto, Hiroki; Kamisaki, Toshiaki; Inoue, Kimihiro; Sato, Makoto
PATENT ASSIGNEE(S): Ajinomoto, Inc., Japan
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9733885	A1	19970918	WO 1997-JP754	19970311
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9702038	A	19970917	ZA 1997-2038	19970310
TW 479057	B	20020311	TW 1997-86102931	19970310
AU 9722335	A1	19971001	AU 1997-22335	19970311
AU 704521	B2	19990422		
EP 889043	A1	19990107	EP 1997-905478	19970311
EP 889043	B1	20010829		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
CN 1213371	A	19990407	CN 1997-193005	19970311
CN 1085209	B	20020522		
BR 9707962	A	19990727	BR 1997-7962	19970311
JP 3127469	B2	20010122	JP 1997-532434	19970311
AT 204871	E	20010915	AT 1997-905478	19970311
ES 2159843	T3	20011016	ES 1997-905478	19970311
PT 889043	T	20020228	PT 1997-905478	19970311
CA 2261271	C	20030916	CA 1997-2261271	19970311
NO 9804162	A	19981105	NO 1998-4162	19980910
US 6127361	A	20001003	US 1998-147012	19980911
US 6436922	B1	20020820	US 2000-597409	20000619
PRIORITY APPLN. INFO.:			JP 1996-83104 A	19960311
			WO 1997-JP754 W	19970311
			US 1998-147012 A1	19980911

OTHER SOURCE(S): MARPAT 127:293256
GI



I

AB The title compds. I [R1, R2 = H, halo, etc.; or R1R2 = O(CH2)nO; n = 1 - 3; R3 = H, OH; R4, R5 = H, OH; or R4R5 = O] are prepared I are calcium antagonists improving the motor function of the digestive tract. In an in vitro test for calcium antagonism using guinea pig ileum fragment, (R)-(+)-5,11-dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenz[b,e][1,4]oxazepine hydrochloride (II) showed IC50 of 85 nM; in the test for calcium antagonism using rat artery fragment, II showed IC50 of 200 nM. II showed no anticholinergic activity. II gave better improvement of the motor function of the digestive tract than nicardipine. In the test for hypotensive activity, II showed ED50 of > 1000 mg/kg p.o., vs. ED50 of 4 mg/kg p.o. for nicardipine.

IT **195991-49-2P 195991-50-5P 195991-51-6P**
195991-52-7P 195991-53-8P 195991-54-9P
195991-55-0P 195991-56-1P 195991-57-2P
195991-58-3P 195991-59-4P 195991-60-7P
195991-61-8P 195991-62-9P 195991-63-0P
195991-64-1P 195991-65-2P 195991-66-3P
195991-67-4P 195991-68-5P 195991-69-6P
195991-70-9P 196959-46-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydrodibenzoxazepine derivs. for improving the motor function of the digestive tract)

RN 195991-49-2 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-50-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-51-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(4-fluorophenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-52-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(4-fluorophenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-53-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-(2-phenylethyl)-2-pyrrolidinyl]methyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-54-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-(2-phenylethyl)-2-pyrrolidinyl]methyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 195991-55-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-56-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-57-2 CAPLUS
CN Benzonitrile, 4-[2-[2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-58-3 CAPLUS
CN Benzonitrile, 4-[2-[2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-59-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 195991-60-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 195991-61-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 195991-62-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 195991-63-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(1,3-benzodioxol-5-yl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 195991-64-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(3-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 195991-65-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(3-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 195991-66-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-(2-phenylethyl)-2-pyrrolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 195991-67-4 CAPLUS
CN 1-Pyrrolidineethanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-α-(4-methoxyphenyl)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 195991-68-5 CAPLUS
CN Ethanone, 2-[2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]-1-(4-methoxyphenyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 195991-69-6 CAPLUS
CN 3-Pyrrolidinol, 5-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-[2-(4-methoxyphenyl)ethyl]-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-70-9 CAPLUS
CN 3-Pyrrolidinol, 5-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-[2-(4-methoxyphenyl)ethyl]-, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 196959-46-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(1,3-benzodioxol-5-yl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT **195991-74-3P 195991-75-4P 195991-80-1P**
195991-81-2P 196710-93-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydrodibenzoxazepine derivs. for improving the motor function of the digestive tract)

RN 195991-74-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)-2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-2-pyrrolidinyl]methyl]-, (2R)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195991-75-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)-2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-2-pyrrolidinyl]methyl]-, (2S)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195991-80-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[4-(methoxymethoxy)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, (2R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195991-81-2 CAPLUS
CN 3-Pyrrolidinol, 5-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-[2-(4-methoxyphenyl)ethyl]-, (3R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 196710-93-7 CAPLUS
CN 3-Pyrrolidinol, 5-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-[2-(4-methoxyphenyl)ethyl]-, benzoate (ester), (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L25 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1991:429390 CAPLUS
DOCUMENT NUMBER: 115:29390
TITLE: Preparation of N-(pyrrolidinyl-or piperidinylalkyl)dibenzo[b,e][1,4]thiazepines as calcium antagonists for treatment of gastrointestinal motility disorders
INVENTOR(S): Alker, David; Bass, Robert J.; Cross, Peter Edward
PATENT ASSIGNEE(S): Pfizer Ltd., UK; Pfizer Inc.
SOURCE: Eur. Pat. Appl., 66 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 404359	A1	19901227	EP 1990-305718	19900525
EP 404359	B1	19940629		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5071844	A	19911210	US 1990-527616	19900523
CA 2017535	AA	19901127	CA 1990-2017535	19900525
CA 2017535	C	20000229		
NO 9002336	A	19901128	NO 1990-2336	19900525
AU 9055954	A1	19901129	AU 1990-55954	19900525
DD 294718	A5	19911010	DD 1990-340993	19900525
HU 58329	A2	19920228	HU 1990-3197	19900525
ES 2055867	T3	19940901	ES 1990-305718	19900525
FI 96950	B	19960614	FI 1990-2632	19900525
FI 96950	C	19960925		
CN 1047673	A	19901212	CN 1990-103954	19900526
JP 03017079	A2	19910125	JP 1990-138177	19900528
JP 05007389	B4	19930128		

PRIORITY APPLN. INFO.: GB 1989-12303 A 19890527
OTHER SOURCE(S): MARPAT 115:29390
GI



I



II





AB The title compds. [I; R1 = H, alkyl; R2 = Q1,Q2, (substituted) pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl; R3,R4 = H, alkyl, alkoxy, OH, dialkylamino, halo, CF3; X1,X2 = O, CH2; X = O, S, bond; k,m,n,q = 1,2,3; p = 0,1,2], were prepared as Ca antagonists for treatment of spasm or hypermotility of smooth muscle (no data). Thus, a prestirred mixture of 5,11-dihydrodibenzo[b,e][1,4]thiazepine and KH in DME was treated with a solution of (R)-3-chloromethyl-1-(4-methoxyphenethyl)piperidine (preparation given) in DME and the mixture was refluxed 18 h to give 12% title compds. II.

IT **133714-92-8P 133714-93-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for dibenzothiazepine calcium antagonists)

RN 133714-92-8 CAPLUS

CN 2-Pyrrolidinemethanamine, N-[2-[[(2-bromophenyl)methyl]thio]phenyl]-1-[2-(4-methoxyphenyl)ethyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 133714-93-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-[[(2-bromophenyl)methyl]thio]phenyl]-1-[(4-methoxyphenyl)acetyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


MeO
O
N
S
HN
O
S
Br

L25 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1975:81187 CAPLUS
DOCUMENT NUMBER: 82:81187
TITLE: Effect of substituted dibenzoxazepines on levels of reduced glutathione and potassium ions in lenses of rabbits in vitro and of rats in vivo
AUTHOR(S): Wong, Keith K.; Wang, Geng Mei; Dreyfuss, Jacques; Schreiber, Eric C.
CORPORATE SOURCE: Dep. Drug Metab., Squibb Inst. Med. Res., New Brunswick, NJ, USA
SOURCE: Journal of Pharmaceutical Sciences (1974), 63(6), 854-7
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Substituted dibenzoxazepines decreased the levels of K+ [7440-09-7] and reduced glutathione (GSH) [70-18-8] in isolated rabbit lenses, the effects of some of the compds. correlating with their tendency to bind to erythrocyte ghosts. The dietary administration of substituted dibenzoxazepines to rats also lowered GSH levels in lenses, the response being greatest in those animals that showed the most severe morphol. changes. Measurement of GSH and K+ levels in lenses may aid in preliminary determination of the cataractogenicity of the dibenzoxazepines. 4-[3-(7-Chloro-5,11-dihydrodibenz[b,e][1,4]oxazepin-5-yl)propyl]-1-piperazineethanol-HCl (I) [41296-98-4] caused the greatest decrease in GSH and K+ of isolated lenses.
IT **7759-15-1 28770-47-0 52454-79-2**
RL: PRP (Properties)
(potassium and reduced glutathione of eye in response to)
RN 7759-15-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 16882-89-6
CMF C17 H20 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 28770-47-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, 3-chloro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 52454-79-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, 7-chloro-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L25 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1974:477985 CAPLUS
DOCUMENT NUMBER: 81:77985
TITLE: N-Oxides of 5-(aminoalkyl)-5,11-dihydrodibenzoxazepines and 5,11-dihydrodibenzthiazepines
INVENTOR(S): Yale, Harry L.; Bernstein, Jack
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3796725	A	19740312	US 1971-110327	19710127
PRIORITY APPLN. INFO.:			US 1969-655352	19690724
			US 1970-17966	19700309

AB The title compds., e.g. I (R = R1 = Me, HOCH2CH2; RR1 = (CH2)4, CH2CH2OCH2CH2, CH2CHMeCH2CH2; R2 = H, Me; n = 1,2,3; X = O, S) and II(R = H, F3C; X = O, S) were prepared by oxidation of the corresponding amines. Thus, 5,11-dihydrobenz[b,e] [1,4] oxazepine was treated with Br(CH2)3Cl followed by (HOCH2CH2)2NH to give 5,11-dihydro-5-[3-[bis(2-hydroxyethyl)amino]propyl]dibenz[b,e] [1,4]oxazepine which was oxidized with 30% HiO2 to give I [R = R1 = HOCH2CH2, R2 = H, X = O, n = 3). At 5-50 mg/kg I and II were antiarrhythmic. At 0.001-0.1% I and II eliminated S. aureus and T. mentagrophytes.

IT **16882-89-6 52694-44-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of)

RN 16882-89-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 52694-44-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-7-sulfonamide, 5-[2-(dimethylamino)ethyl]-5,11-dihydro- (9CI) (CA INDEX NAME)



IT **52694-21-0P 52694-45-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 52694-21-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-, N-oxide, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 47132-34-3
CMF C17 H20 N2 O2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 52694-45-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-7-sulfonamide, 5-[2-(dimethyloxidoamino)ethyl]-5,11-dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



L25 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1973:413382 CAPLUS
DOCUMENT NUMBER: 79:13382
TITLE: Distribution of dibenzoxazepines bearing the carboxamide or other side chains in ocular and other tissues of dogs
AUTHOR(S): Dreyfuss, Jacques; Shaw, James M.; Ross, John J., Jr.; Wang, Geng Mei; Wong, Keith K.; Schreiber, Eric C.
CORPORATE SOURCE: Dep. Drug. Metab., Squibb Inst. Med. Res., New Brunswick, NJ, USA
SOURCE: Journal of Pharmaceutical Sciences (1973), 62(4), 606-9
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English

AB After oral or i.v. administration of labeled [4-[3-(7-chloro-5,11-dihydrodibenz[b,e][1,4]oxazepin-5-yl)propyl]-1-piperazinyl]ethanol-HCl [40671-55-4], its trifluoromethyl analog, or 5-[2-(dimethylamino)ethyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine maleate [**19625-12-8**] to dogs, greater concns. of radioactivity were found in the organs, especially the brain, liver, lungs, and melanin-containing portions of the eye, than in the blood. The same compds. were bound to various extents to melanin granules of beef eyeball in vitro. However, 7-chloro-5,11-dihydrodibenz[b,e][1,4]oxazepine-5-carboxamide (I) [16802-77-0] was neither localized in any tissues of the dog, relative to concns. in the blood, nor bound to melanin granules in vitro. Thus, the presence of the carboxamide side chain alters I affinity for tissues, especially those containing melanin.

IT **7759-15-1**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metabolism of, by eye and other tissues)
RN 7759-15-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 16882-89-6
CMF C17 H20 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.


HO2C
Z
CO2H

L25 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1973:111389 CAPLUS
DOCUMENT NUMBER: 78:111389
TITLE: 5,11-Dihydrodibenzoxazepines derivatives
INVENTOR(S): Yale, Harry L.; Sowinski, Frances A.
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.
SOURCE: U.S., 8 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3714192	A	19730130	US 1970-76285	19700928
PRIORITY APPLN. INFO.:			US 1965-438406	19650309
			US 1967-668632	19670918

GI For diagram(s), see printed CA Issue.
AB (Anilinobenzyl)dihydrodibenzoxazepine I (R = Me2NCH2CH2) and its salts, which possess hypotensive, antibacterial, antifungal, and tumor inhibition activity, was prepared by reaction of dihydrodibenzoxazepine II (R = Me2NCH2CH2) with excess NaH and 2 equivs. Me2NCH2CH2Cl in refluxing THF.
IT **16882-89-6P 19625-12-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 16882-89-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 19625-12-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 16882-89-6
CMF C17 H20 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L25 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1972:501692 CAPLUS
DOCUMENT NUMBER: 77:101692
TITLE: 5-(Aminoalkyl)-5,11-dihydrodibenzoxazepine and 5,11-dihydrodibenzothiazepine N-oxides with antibacterial and antiarryhthmic activity
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.
SOURCE: Fr. Demande, 12 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2085631	B1	19730608	FR 1970-12720	19700408

PRIORITY APPLN. INFO.: FR 1970-12720 19700408

GI For diagram(s), see printed CA Issue.

AB The dibenzoxazepines (I, R = H, CF3; R1 = N(O)Me2, 1-methyl-3-piperidyl, Cl, 4-(2-hydroxyethyl)-1-piperazinyl; n = 1-3) were prepared Thus I (R = H, R1 = 1-methyl-3-piperidyl, n = 1) was obtained by treating 5,11-dihydrodibenzo[b,e] [1,4]oxazepine with (1-methyl-3-piperidyl)-methyl chloride in the presence of NaH. I (R = H, R1 = N(O)Me2, n = 2) was obtained by H2O2 oxidation of I (R = H, R1 = NMe2, n = 2).

IT **36693-39-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 36693-39-7 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-, 5-oxide, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 47111-46-6
CMF C17 H20 N2 O2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L25 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1972:144876 CAPLUS
DOCUMENT NUMBER: 76:144876
TITLE: Qualitative and quantitative analysis of the psychopharmaceuticals, bromazepam, sulazepam, prazepam, nitrazepam, Tegretol, Noveril, Anafranil, Etumine, and SQ-10648
AUTHOR(S): Dobrecky, Jose; Gonzalez, Beatriz; Molinari Espeche, Ana M.
CORPORATE SOURCE: Fac. Farm. Bioquim., Univ. Nac. Buenos Aires, Buenos Aires, Argent.
SOURCE: Revista de la Asociacion Bioquimica Argentina (1971), 36(196-197), 214-25
CODEN: RABAAO; ISSN: 0004-4768
DOCUMENT TYPE: Journal
LANGUAGE: Spanish
AB The title drugs were quant. and qual determined volumetrically in nonaq. media and heterogenous phases; gravimetrically with silico-tungstates; colorimetrically with reineckates, Co and K thiocyanates; and spectrophotometrically in various solvents.
IT **16882-89-6**
RL: ANST (Analytical study)
(detection and determination of)
RN 16882-89-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl- (9CI) (CA INDEX NAME)



L25 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1972:127032 CAPLUS
DOCUMENT NUMBER: 76:127032
TITLE: 5,11-Dihydrodibenz[b,e][1,4]oxazepine derivatives
INVENTOR(S): Yale, Harry L.
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3631052	A	19711228	US 1970-10982	19700212

PRIORITY APPLN. INFO.: US 1970-10982 19700212

GI For diagram(s), see printed CA Issue.

AB Antianxiety title compds. (I) were prepared NaOMe-EtOH was added dropwise to a mixture of 5-trifluoromethyl-2-hydroxyformanilide and 4-chloro-2-bromobenzyl bro mide in EtOH to give 2-(4-chloro-2-bromobenzyloxy)-5-tri-fluoromethylformanilide (II). A mixture of II, DMF, K2CO3, and copper bronze was heated 3.5 hr. to give 3-chloro-5,11-dihydro-7-(trifluoromethyl)dibenz[b,e][1,4]oxazepine - 5 - carboxaldehyde, from which the formyl group was removed by reflux with 25% aqueous NaOH to give 3-chloro-5,11-dihydro-7-(trifluoromethyl)dibenz-[b,e][1.4]oxazepine (III). A mixture of III, 2-[2-[2-(dimethylamino)ethyl]piperidino]ethyl chloride-HBr, AcEt, and NaOH was refluxed 3 hr to give I (R = Cl, R1 = 2-[2-(dimethylamino)-ethyl]piperidino, n = 2). Similarly prepared was I [R = H, R1 = 4-(2-tetrahydropyranyloxy), n = 4] which, treated with concentrate HCl gave I (R = H, R1 = OH, n = 4), which, treated with SOCl2 gave I (R = H, R1 = Cl, n = 4), which, refluxed 18 hr with 3-(2-aminobutyl)piperidine, NaI, and AcEt gave I [R = H, R1 = 3-(2-aminobutyl)piperidine, n = 4]. I (R = H, R1 = 4-(aminomethyl)piperidino, n = 3) was similarly prepared

IT **36080-79-2P 36412-96-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 36080-79-2 CAPLUS
CN 2-Piperidineethanamine, 1-[2-[3-chloro-7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 36412-96-1 CAPLUS

CN 2-Piperidineethanamine, 1-[2-[3-chloro-7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]ethyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 36080-79-2
CMF C25 H31 Cl F3 N3 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L25 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1972:14605 CAPLUS
DOCUMENT NUMBER: 76:14605
TITLE: 5-(Aminoalkyl)-5,11-dihydrodibenz[b,e][1,4]oxazepine and -thiazepine N-oxides and their acid addition salts
INVENTOR(S): Yale, Harry L.; Bernstein, Jack
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.
SOURCE: Ger. Offen., 14 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2016356	A	19711028	DE 1970-2016356	19700406

PRIORITY APPLN. INFO.: DE 1970-2016356 19700406
GI For diagram(s), see printed CA Issue.
AB I and their salts were prepared Thus, 5-[2-dimethylamino)ethyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine was refluxed 3.5 hr with 30% H2O2 in 95% EtOH to give I [R = (CH2)2N(O)Me2, R1 = H], which was treated with maleic acid in Me2CO to give the corresponding maleate. Similarly prepared were several other I, including I [R = 3-[4-(2-hydroxyethyl)-1-piperazinyl]propyl, R1 = CF3], its N-oxide, and N-oxide dimaleate.
IT **35019-29-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 35019-29-5 CAPLUS
CN Dibenz[b,e][1,4]-oxazepine-5(11H)-ethanamine, N,N-dimethyl-, N-oxide, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 47132-34-3
CMF C17 H20 N2 O2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.


HO2C
Z
CO2H

L25 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1971:141906 CAPLUS
DOCUMENT NUMBER: 74:141906
TITLE: Adamantyl dibenzoxazepines as antihistaminic, antiparkinsonism tranquilizing, and sedative agents
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.
SOURCE: Fr. M., 7 pp.
CODEN: FMXXAJ
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 6892		19690604	FR	19670626

GI For diagram(s), see printed CA Issue.

AB The title compds., e.g., I, were prepared by known reactions. Thus, 1-adamantanecarbonyl chloride was converted to the amide with 1-benzylpiperazine, the amide debenzylated with H over Pd/C, and the product reduced with LiAlH4 to 1-(1-adamantylmethyl)piperazine (II). II with Cl(CH2)3Br gave the 4-(3-chloropropyl) derivative, which reacted with the Na derivative of 5,11-dihydrodibenz[b,e][1,4]-oxazepine to give I.

IT **17972-55-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17972-55-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(1-adamantylmethylamino)ethyl]-5,11-dihydro- (8CI) (CA INDEX NAME)



L25 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1970:477294 CAPLUS
DOCUMENT NUMBER: 73:77294
TITLE: Adamantane derivatives, having depressant and antihistaminic activity
INVENTOR(S): Bernstein, Jack
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.
SOURCE: Brit., 9 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1198852		19700715	GB	19670613

GI For diagram(s), see printed CA Issue.

AB A series of title compds. was prepared Thus, ClCH2CH2COCl in C6H6 added dropwise with ice-cooling to 1-(methylamino)adamantane in C6H6 and the mixture refluxed 5 hr gave N-(1-adamantyl)-3-chloro-N-methylpropionamide, converted by reduction with LiAlH4 in Et2O into N-(3-chloropropyl)-N-methyl-1-adamantylamine (I). NaH (50% dispersion in mineral oil) and 5,11-dihydrodibenz[b,e][1,4]oxazepine stirred 1 hr in THF with N bubbled through the mixture with dropwise addition of I in THF, and the mixture refluxed 3 hr gave 5-[3-(N-methyl-1-adamantylamino)propyl]-5,11-dihydrodibenz[b,e][1, 4]oxazepine(II). For other examples were given. Title compds. have central nervous system depressant activity and antihistaminic activity and are useful in the treatment of allergies, Parkinsonism or as tranquilizers or sedatives.

IT **17972-55-3P 28846-19-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 17972-55-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(1-adamantylmethylamino)ethyl]-5,11-dihydro- (8CI) (CA INDEX NAME)



RN 28846-19-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(1-adamantylmethylamino)ethyl]-5,11-dihydro-, maleate (8CI) (CA INDEX NAME)

CM 1

CRN 17972-55-3
CMF C26 H32 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L25 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1970:445482 CAPLUS
DOCUMENT NUMBER: 73:45482
TITLE: Novel polycyclic heterocycles. Derivatives of 5,11-dihydrodibenz[b,e][1,4]oxazepine and 5,11-dihydrodibenzo[b,e][1,4]thiazepine
AUTHOR(S): Yale, Harry L.; Beer, Bernard; Pluscec, Jelka; Spitzmiller, Erwin R.
CORPORATE SOURCE: Squibb Inst. for Med. Res., New Brunswick, NJ, USA
SOURCE: Journal of Medicinal Chemistry (1970), 13(4), 713-22
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB 5-Substituted 5,11-dihydrodibenz[b,c][1,4]oxazepines (e.g. I) and 5,11-dihydrodibenzo[b,e][1,4]thiazepines were prepared When the 5-substituent is 3-[1-(2-hydroxyethyl)-4-piperazinyl]propyl and a substituent like Cl or CF3 is in the 3 or 7 position, the compounds show antianxiety effects at lower doses and central nervous system depressant activity at higher doses. When the 5 substituent is a simple dialkylaminoalkyl group, the compounds are not depressants at either dose level, but instead are stimulants, but only at the higher dose range.
IT **19367-70-5P 24513-28-8P 28667-31-4P**
28713-69-1P 28713-71-5P 28753-36-8P
28770-47-0P 28770-48-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 19367-70-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)- (8CI) (CA INDEX NAME)



RN 24513-28-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)-, maleate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 19367-70-5
CMF C20 H23 F3 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 28667-31-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5-[2-(dimethylamino)ethyl]-5,11-dihydro-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 28713-69-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(dimethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)-, maleate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 47339-96-8
CMF C18 H19 F3 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 28713-71-5 CAPLUS
CN 1-Piperazineethanol, 4-[2-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]ethyl]-, maleate (1:2) (salt) (8CI) (CA INDEX NAME)

CM 1

CRN 47650-26-0
CMF C22 H26 F3 N3 O2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 28753-36-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-bromo-3-chloro-5-[2-(dimethylamino)ethyl]-5,11-dihydro-, phosphate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 28770-48-1
CMF C17 H18 Br Cl N2 O



CM 2

CRN 7664-38-2
CMF H3 O4 P



RN 28770-47-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, 3-chloro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 28770-48-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 2-bromo-3-chloro-5-[2-(dimethylamino)ethyl]-5,11-dihydro- (8CI) (CA INDEX NAME)



L25 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1970:12782 CAPLUS
DOCUMENT NUMBER: 72:12782
TITLE: 5-(Aminoalkyl)-5,11-dihydrodibenzoxazepines
INVENTOR(S): Yale, Harry L.; Restivo, Albert R.
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.
SOURCE: Brit., 3 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1156162		19690625	GB	19660822

GI For diagram(s), see printed CA Issue.

AB The title compds. I are prepared by refluxing II with ClCH2CH2NR2. The yields are considerably increased by using excess powdered NaOH (≥4 molar equivs.) in acetone, or excess NaH (≥1.2 molar equivs.) in dry tetrahydrofuran. In an example, 10 g II (Z = H), 24 ml ClCH2CH2NMe2, and 16 g NaOH in 100 ml acetone was refluxed 2 hr. The mixture was worked up, the product dissolved in acetone and maleic acid in acetone added, then Et2O added to give 72% I (R = Me, Z = H), as the maleate m. 141-2°. Also prepared were I (R = Me, Z = CF3), maleate, m. 166-8°, and I (R = Et, Z = CF3), b0·2 152-7°, maleate m. 147-9°. I have physiological activity.

IT **19367-70-5P 19442-88-7P 19442-89-8P**
19625-12-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 19367-70-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)- (8CI) (CA INDEX NAME)



RN 19442-88-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(dimethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)-, maleate (8CI) (CA INDEX NAME)

CM 1

CRN 47339-96-8
CMF C18 H19 F3 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 19442-89-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)-, maleate (8CI) (CA INDEX NAME)

CM 1

CRN 19367-70-5
CMF C20 H23 F3 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 19625-12-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 16882-89-6
CMF C17 H20 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L25 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1968:487030 CAPLUS
DOCUMENT NUMBER: 69:87030
TITLE: Preparation of 5-(aminoalkyl)-5,11-dihydrodibenzoxazepines and dihydrodibenzothiazepines
INVENTOR(S): Yale, Harry L.; Restivo, Albert R.
PATENT ASSIGNEE(S): Squibb, E.R., and Sons, Inc.
SOURCE: U.S., 2 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3387002	A	19680604	US 1965-488266	19650917

PRIORITY APPLN. INFO.: US 1965-488266 19650917

GI For diagram(s), see printed CA Issue.

AB The 5-(aminoalkyl)-5,11-dihydrodibenzoxazepines (I) and 5-(aminoalkyl)-5,11-dihydrodibenzothiazepines (II) are prepared by treating 5,11-dihydrodibenzoxazepines or 5,11-dihydrodibenzothiazepines with an aminoalkyl halide and a 4 molar excess of NaOH in Me2CO or NaH in dry tetrahydrofuran (THF). Thus, I (R = Me, R2 = H)-maleate (III) was prepared by refluxing 10 g. 5,11-dihydrodibenz[b,e][1,4]oxazepine, 24 ml. Me2NCH2CH2Cl and 16 g. powdered NaOH in 100 ml. Me2CO 2 hrs. to give 72% III, m. 141-2°. An 80% yield of the same product was obtained using a 50% dispersion of NaH in mineral oil and refluxing in dry THF under N. If THF was used in place of Me2CO with NaOH the yield was reduced to 39% and if C6H6 or PhMe were used as solvents no product was obtained. A 64% yield of I (R = Me, R1 = 7-CF3, R2 = H)-maleate m. 166-8° and an 80% yield of I (R = Et, R1 = 7-CF3, R2 = H), b. 152-7°, was obtained by reacting 5,11-dihydro-7-(trifluoromethyl)dibenz[b,e][1,4]oxazepine with Me2NCH2CH2Cl and Et2NCH2CH2Cl resp. in the presence of NaOH in Me2CO. II (R = Me, R1 = R2 = H), b. 180° and the maleate derivative m. 154-5° were prepared from 5,11-dihydrodibenzo[b,e][1,4]thiazepine.

IT **19367-70-5P 19442-88-7P 19442-89-8P**
19625-12-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 19367-70-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)- (8CI) (CA INDEX NAME)



RN 19442-88-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(dimethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)-, maleate (8CI) (CA INDEX NAME)

CM 1

CRN 47339-96-8
CMF C18 H19 F3 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 19442-89-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)-, maleate (8CI) (CA INDEX NAME)

CM 1

CRN 19367-70-5
CMF C20 H23 F3 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 19625-12-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 16882-89-6
CMF C17 H20 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L25 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1968:443950 CAPLUS
DOCUMENT NUMBER: 69:43950
TITLE: 5-(Aminoalkyl)-5,11-dihydrodibenzo[b,e] [1,4]oxazepins
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.
SOURCE: Fr., 2 pp.
CODEN: FRXXAK
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 1491073		19670804	FR	19660109

GI For diagram(s), see printed CA Issue.

AB Compds. of the general formula I are prepared from 5,11-dihydrodibenzo[b,e] [1,4]-oxazepine (II), and derivs. of II, and compds. of the general formula R2NCH2CH2Cl in Me2CO in the presence of NaOH and in tetrahydrofuran in the presence of NaH. A mixture of 10 g. II, 24 ml. Me2NCH2CH2Cl, 16 g. NaOH, and 100 ml. Me2CO is refluxed 2 hrs., cooled, and filtered; the product is treated with maleic acid to give 72% 2-(dimethylaminoethyl)-5, 11-dihydrodibenzo-[b,e] [1,4] oxazepine maleate, m. 141-2°. Similarly prepared are the following I (R1 = CF3) (R, b.p./mm., and m.p. maleate given): Me, -, 166-8°; and Et, 152-7° /0.2, 147-9°.

IT **19367-70-5P 19442-88-7P 19442-89-8P**
19625-12-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 19367-70-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)- (8CI) (CA INDEX NAME)



RN 19442-88-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(dimethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)-, maleate (8CI) (CA INDEX NAME)

CM 1

CRN 47339-96-8
CMF C18 H19 F3 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 19442-89-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)-, maleate (8CI) (CA INDEX NAME)

CM 1

CRN 19367-70-5
CMF C20 H23 F3 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 19625-12-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 16882-89-6
CMF C17 H20 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L25 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1968:95870 CAPLUS
DOCUMENT NUMBER: 68:95870
TITLE: Adamantylamino(and piperazino)-5,11-dihydrodibenz[b,e][1,4]oxazepines
INVENTOR(S): Bernstein, Jack
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3338900		19670829	US	19650726
FR 1552841			FR	

GI For diagram(s), see printed CA Issue.

AB Compds. of type I [where R = R1 = H, halo, lower alkyl, Ph, alkoxy, R2 = H, halo, CF3, R3 = H, halo, CF3, alkyl, alkoxy, Me2SO2NH, CF3S, Z = amino, alkylamino, piperazino, Q = alkylene, m = 0-2, n = 1-3] having central depressant and antihistaminic activity can be prepared by reacting adamantanamine with haloacyl halide followed by reduction and condensation with 5,11-dihydrobenz[b,e][1,4]oxazepine. Thus, 37.1 g. ClCH2CH2COCl in 100 ml. dry C6H6 was added dropwise to 100 g. 1-(methylamino)adamantane (II) in C6H6, the mixture refluxed 5 hrs., washed and dried, and solvent removed to give N-(1-adamantyl)-3-chloro-N-methylpropionamide which on reduction with LiAlH4 yielded N-(3-chloropropyl)-N-methyl-1-adamantanamine (III). A mixture of 4.9 g. 5,11-dihydrodibenz[b,e][1,4]oxazepine (IV), 1.5 g. NaH (50% in mineral oil), and 50 ml. tetrahydrofuran (THF) is stirred 1 hr. under N, a solution of 18 g. III in THF added, the mixture refluxed 3 hrs. and filtered, the filtrate concentrated and diluted with Et2O, the Et2O solution extracted with 10% H3PO4, and the acid extract made basic, extracted with Et2O, and dried over MgSO4 to give 5-[3-(N-methyl-1-adamantylamino)propyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine; the HCl salt was prepared in the usual manner. 2-(N-Methyl-1-adamantylamino)ethanol (V) is prepared by condensation of II with ethylene oxide in THF at 70°, which on treatment with SOBr2 in CHCl3 gave N-(2-bromoethyl)-N-methyl-1-adamantylamine hydrobromide (VI). Condensation of VI and IV with NaH yields 5-[2-(N-methyl- 1 - adamantylamino)ethyl] - 5,11 - dihydrodibenz[b,e][1,4]oxazepine. Similarly prepared were: 5-[2-(N-ethyl-3-methyl-1 - adamantylamino)ethyl - 5,11 - dihydrobenz[b,e][1,4]oxazepine (as maleate), 5-[3-(N-methyl-3-methoxy-1-adamantylmethylamino)propyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine (as HCl salt), 5-[3-[4-(1 - adamantylmethyl)-1-piperazinyl]propyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine (as di-HCl salt), and 5-[3-[4-[2-(1-adamantyl)ethyl]- 1- piperazinyl]propyl] - 5,11 - dihydrodibenz[b,e][1,4]oxazepine (as di-HCl salt).

IT **17972-55-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 17972-55-3 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5-[2-(1-adamantylmethylamino)ethyl]-5,11-dihydro- (8CI) (CA INDEX NAME)


O
N
CH2
CH2
N
Me

L25 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1968:29690 CAPLUS
DOCUMENT NUMBER: 68:29690
TITLE: Novel polycyclic heterocycles. IV. Structure of the dimer of 5,11-dihydrodibenz[b,e][1,4]oxazepine. Infrared, proton magnetic resonance, and mass spectral studies
AUTHOR(S): Yale, Harry L.; Sowinski, Francis A.
CORPORATE SOURCE: Squibb Inst. for Med. Res., New Brunswick, NJ, USA
SOURCE: Journal of Medicinal Chemistry (1967), 10(6), 1022-5
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB In the synthesis of 5-[2-(dimethylamino)ethyl]-5,11-dihydrodibenz [b,e] [1,4] oxazepine (I), by the reaction of the anion of the heterocycle with 2-dimethylaminoethyl chloride, one of the by-products isolated from the residue from the distillation of I was identified as 5-[o-[o-[2-(dimethylamino)-ethoxy] - N - [2 - (dimethylamino)ethyl]anilino]benzyl]5,11 - dihydrodibenz[b,e] [1,4]oxazepine (II). In the absence of 2-dimethylaminoethyl chloride, the anion of the heterocycle forms the parent dimer, 5-[o-(o-hydroxyanilino)benzyl]-5,11-dihydrodibenz[b,e] [1,4]oxazepine. The ir, P.M.R., and mass spectra of these and related compds. are discussed.
IT **16882-89-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(mass spectrum and N.M.R. of)
RN 16882-89-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl- (9CI) (CA INDEX NAME)



L25 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1964:461683 CAPLUS
DOCUMENT NUMBER: 61:61683
ORIGINAL REFERENCE NO.: 61:10686g-h,10687a-b
TITLE: Novel polycyclic heterocycles. II. Derivatives of 5,11-dihydrodibenz[b,e][1,4]oxazepine
AUTHOR(S): Yale, Harry L.; Sowinski, Francis
CORPORATE SOURCE: Squibb Inst. for Med. Res., New Brunswick, NJ
SOURCE: Journal of Medicinal Chemistry (1964), 7(5), 609-14
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 61:61683
GI For diagram(s), see printed CA Issue.
AB cf. CA 60, 14472f. 5,11-Dihydrodibenz[b,e][1,4]oxazepine (I) was prepared by the following sequence: o-bromobenzyl o-nitrophenyl ether → o-(o-bromobenzyloxy)aniline → 2-(o-bromobenzyloxy)formanilide → 5,11-dihydrodibenz[b,e][1,4]oxazepine-5-carboxaldehyde → I. A related synthesis gave 7-chloro-5,11-dihydrodibenz[b,e][1,4]oxazepin e (II). 2-(2,4-Dichlorobenzyloxy)formanilide could not be made to cyclize. Alkylation of I and II with dialkylaminoalkyl chlorides was bes carried out with NaH in Me2SO. In addition I and II were allowed to react with 3-chloropropionyl chloride and the resulting 5-(3-chloropropionyl) derivs. converted to 5-(3-monoalkyl- and 3-dialkylaminoacyl) derivs. I and COCl2 gave the 5-carbonyl chloride, and this derivative with dialkylaminoalcs. and dialkylaminoalkylamines gave the corresponding urethans and carbamates, resp. 5-(3-Monoalkylaminopropyl) derivs. of I and II were prepared by reaction first with N-(3-chloropropyl)-N-methylformamide and then removal of the blocking formyl group by saponification Several of the compds. are active as antihistamines and as antipruritic agents.
IT **7759-15-1**, Dibenz[b,e][1,4]oxazepine, 5-[2-(dimethylamino)ethyl]-5,11-dihydro-, maleate (1:1) **16882-89-6**, Dibenz[b,e][1,4]oxazepine, 5-[2-(dimethylamino)ethyl]-5,11-dihydro- **52454-79-2**, Dibenz[b,e][1,4]oxazepine, 7-chloro-5-[2-(dimethylamino)ethyl]-5,11-dihydro-, hydrochloride **98742-07-5**, Dibenz[b,e][1,4]oxazepine, 7-chloro-5-[2-(dimethylamino)propyl]-5,11-dihydro- **99690-03-6**, Dibenz[b,e][1,4]oxazepine, 5-[2-(dimethylamino)propyl]-5,11-dihydro- **99750-02-4**, Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-, hydrochloride
(preparation of)
RN 7759-15-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 16882-89-6
CMF C17 H20 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 16882-89-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 52454-79-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, 7-chloro-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 98742-07-5 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 7-chloro-5-[2-(dimethylamino)propyl]-5,11-dihydro- (7CI) (CA INDEX NAME)



RN 99690-03-6 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(dimethylamino)propyl]-5,11-dihydro- (7CI) (CA INDEX NAME)



RN 99750-02-4 CAPLUS
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-, hydrochloride (7CI) (CA INDEX NAME)